References
- Ross H , HowlettJ , ArnoldJMet al. Treating the right patient at the right time: access to heart failure care . Can. J. Cardiol.22 ( 9 ), 749 – 754 ( 2006 ).
- Azad N , LemayG . Management of chronic heart failure in the older population . J. Geriatr. Cardiol.11 ( 4 ), 329 – 337 ( 2014 ).
- Manuel DG , LeungM , NguyenKet al. Burden of cardiovascular disease in Canada . Can. J. Cardiol.19 ( 9 ), 997 – 1004 ( 2003 ).
- Phillips KA , VeenstraD , Van BebberSet al. An introduction to cost–effectiveness and cost-benefit analysis of pharmacogenomics . Pharmacogenomics4 ( 3 ), 231 – 239 ( 2003 ).
- Vernon JA , HughenK , GolecJH . Future of drug development: the economics of pharmacogenomics . Expert Rev. Clin. Pharmacol.1 ( 1 ), 49 – 59 ( 2008 ).
- Wong WB , CarlsonJJ , TharianiRet al. Cost effectiveness of pharmacogenomics: a critical and systematic review . PharmacoEconomics28 ( 11 ), 1001 – 1013 ( 2010 ).
- Payne K , ShabaruddinFH . Cost–effectiveness analysis in pharmacogenomics . Pharmacogenomics11 ( 5 ), 643 – 646 ( 2010 ).
- Veenstra DL , HigashiMK , PhillipsKA . Assessing the cost-effectiveness of pharmacogenomics . AAPS PharmSci2 ( 3 ), E29 ( 2000 ).
- Flowers CR , VeenstraD . The role of cost–effectiveness analysis in the era of pharmacogenomics . PharmacoEconomics22 ( 8 ), 481 – 493 ( 2004 ).
- Phillips KA , Van BebberSL . A systematic review of cost–effectiveness analyses of pharmacogenomic interventions . Pharmacogenomics5 ( 8 ), 1139 – 1149 ( 2004 ).
- Beaulieu M , de DenusS , LachaineJ . Systematic review of pharmacoeconomic studies of pharmacogenomic tests . Pharmacogenomics11 ( 11 ), 1573 – 1590 ( 2010 ).
- Phillips KA , Ann SakowskiJ , TrosmanJet al. The economic value of personalized medicine tests: what we know and what we need to know . Genet. Med.16 ( 3 ), 251 – 257 ( 2014 ).
- Phillips KA , Van BebberSL . Measuring the value of pharmacogenomics . Nat. Rev. Drug Discov.4 ( 6 ), 500 – 509 ( 2005 ).
- Dervieux T , BalaMV . Overview of the pharmacoeconomics of pharmacogenetics . Pharmacogenomics7 ( 8 ), 1175 – 1184 ( 2006 ).
- FDA . Food and Drug Administration approves Corlanor to treat heart failure . www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm442978.htm
- Swedberg K , KomajdaM , BohmMet al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study . Lancet376 ( 9744 ), 875 – 885 ( 2010 ).
- Cheung Wing B . Corlanor (ivabradine) side effects, dosage, cost, approval and prescribing information for chronic heart failure . http://evrt.rxeconsult.com/healthcare-articles/Corlanor-ivabradine-Side-Effects-Dosage-Cost-Approval-and-Prescribing-Information-for-Chronic-Heart-Failure-806/
- Amgen . Information for Vermont prescribers of prescription drugs . Corlanor® (ivabradine) tablets ( 2015 ). www.corlanorhcp.com/∼/media/amgen/full/www-corlanorhcp-com/pdf/vermontpricingform.ashx
- RAMQ. Régie de l’assurance maladie du Québec . List of medications . www.ramq.gouv.qc.ca/fr/regie/publications-legales/Pages/liste-medicaments.aspx
- Sonnenberg FA , BeckJR . Markov models in medical decision making: a practical guide . Med. Decis. Making13 ( 4 ), 322 – 338 ( 1993 ).
- Guidelines for the economic evaluation of health technologies : Canada ( 3rd Edition ). Ottawa : Canadian Agency for Drug and Technologies in Health ( 2006 ). www.inahta.org/wp-content/themes/inahta/img/AboutHTA_Guidelines_for_the_Economic_Evaluation_of_Health_Technologies.pdf
- New York Heart Association , MarvinHM . Diseases of the heart and blood vessels: nomenclature and criteria for diagnosis (6th) . JAMA Intern. Med.113 ( 6 ), 906 – 907 ( 1964 ).
- Miller RJ , HowlettJG , ExnerDVet al. Baseline functional class and therapeutic efficacy of common heart failure interventions: a systematic review and meta-analysis . Can. J. Cardiol.31 ( 6 ), 792 – 799 ( 2015 ).
- CRD. Centre for Reviews and Dissemination . Systematic reviews: CRD’s guidance for undertaking reviews in healthcare ( 2009 ). www.york.ac.uk/media/crd/Systematic_Reviews.pdf
- Stovold E , BeecherD , FoxleeRet al. Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram . Syst. Rev.3 , 54 ( 2014 ).
- Flather MD , ShibataMC , CoatsAJet al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) . Eur. Heart J.26 ( 3 ), 215 – 225 ( 2005 ).
- Ford E , AdamsJ , GravesN . Development of an economic model to assess the cost–effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia . BMJ Open2 ( 5 ), pii:e001094 ( 2012 ).
- Yao G , FreemantleN , FlatherMet al. Long-term cost–effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model . PharmacoEconomics26 ( 10 ), 879 – 889 ( 2008 ).
- Muntwyler J , AbetelG , GrunerCet al. One-year mortality among unselected outpatients with heart failure . Eur. Heart J.23 ( 23 ), 1861 – 1866 ( 2002 ).
- Ahmed A , AronowWS , FlegJL . Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function . Am. Heart J.151 ( 2 ), 444 – 450 ( 2006 ).
- Borer JS , BohmM , FordIet al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT study . Eur. Heart J.33 ( 22 ), 2813 – 2820 ( 2012 ).
- StatisticsCanada. Table 102-0504 – Deaths and mortality rates, by age group and sex, Canada, provinces and territories, annual, CANSIM (database) . www5.statcan.gc.ca/cansim/a26?lang=eng&id=1020504
- Griffiths A , ParachaN , DaviesAet al. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective . Heart100 ( 13 ), 1031 – 1036 ( 2014 ).
- NICE . The National Institute for Health and Care Excellence. Single technology appraisal (STA) specification for manufacturer/sponsor submission of evidence . Heart failure (chronic) – ivabradine: Servier Laboratories Ltd . www.nice.org.uk/guidance/ta267/documents/heart-failure-chronic-ivabradine-servier-laboratories-ltd2
- RAMQ . Régie de l’assurance maladie du Québec (RAMQ). Manuel de facturation des médecins spécialistes (no. 150) . www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/manuels/150-facturation-specialistes/000_complet_acte_spec.pdf
- OCCI. Ontario Case Costing Initiative . OCCI costing analysis tool ( 2015 ). www.irma-international.org/viewtitle/116247/
- McKelvie RS , MoeGW , EzekowitzJAet al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure . Can. J. Cardiol.29 ( 2 ), 168 – 181 ( 2013 ).
- GAC . Ontario Guidelines Advisory Committee. CHF: standard drug therapy ( 2007 ). www.gacguidelines.ca/site/GAC_Guidelines/assets/pdf/CHF07_Atrial_Fibrillation_Summary.pdf
- GAC . Ontario Guidelines Advisory Committee. Summary of recommended guideline. CHF: standard drug therapy ( 2009 ). www.gacguidelines.ca/site/GAC_Guidelines/assets/pdf/CHF07_Standard_Drug_Therapy_Summary.pdf
- Weinstein MC , O’BrienB , HornbergerJet al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices – modeling studies . Value Health6 ( 1 ), 9 – 17 ( 2003 ).
- Husereau D , DrummondM , PetrouSet al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) – explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force . Value Health16 ( 2 ), 231 – 250 ( 2013 ).